UECKER DARRIN
Known title: DirectorCIK: 0001276311
Associated companies
Transaction History
| PLSE | ▲ Buy | Option Exercise | 20,000 | $80K | 9/17/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $324K | 9/17/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 61,534 | $246K | 9/17/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 100,000 | $400K | 9/17/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 25,000 | $100K | 9/16/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 25,000 | $407K | 9/16/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 25,000 | $394K | 9/15/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 25,000 | $100K | 9/15/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 25,000 | $358K | 9/12/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 25,000 | $100K | 9/12/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 25,000 | $100K | 9/11/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 25,000 | $370K | 9/11/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 15,000 | $240K | 6/13/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 15,000 | $246K | 6/12/2025 | View on chart |
| PLSE | ▼ Sell | Other | 7,365 | $15K | 6/12/2023 | View on chart |
| PLSE | ▼ Sell | Other | 7,365 | — | 6/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.